Background In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, none have achieved the accuracy to be inc...
Rodrigo Martinez Alcala, L. Visser, C. Fortpied et al.· PLoS ONE· 0 citations
This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, tha...
Abdulrahman Nasiri, R. El Fakih, C. Chabannon et al.· Bone Marrow Transplantation· 1 citation
The EBMT community strongly supports an expanded global role focused on education, capacity building, and collaboration in underserved regions, and support for LMIC capacity building.
A. Nagler, N. Gorin, C. Chabannon et al.· Bone Marrow Transplantation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
